Cerebrolysin, 10 ml 5 pcs

Cerebrolysin is a stimulator of neurometabolic processes (has nootropic effect).

Deproteinized hydrolysate of pig brain substance stimulates cell differentiation processes, improves the functional state of cells of the nervous system and activates mechanisms of protection and renewal.

The experiments conducted on animals have shown that the amino acids and peptides contained in Cerebrolysine have a direct effect on neuronal and synaptic plasticity, which in turn improves higher brain functions.

Indications

Alzheimer’s disease, Attention and memory disorders, Learning disabilities, Asthenia, Acquired dementia, Headaches, Stroke sequelae, Mental retardation in children, Depression, Concussion and other brain injuries

.

Active ingredient

Brain Peptide Complex

Composition

Active substance:

1 ml of aqueous solution of the drug contains 215.2 mg of Cerebrolysin concentrate (complex of peptides derived from the pig brain).

The active fraction of Cerebrolysin is represented by peptides,

the molecular weight of which does not exceed 10,000 daltons.

Excipients

Sodium hydroxide and water for injection.

How to take, the dosage

Intramuscularly (up to 5 ml), intravenously (up to 10 ml), intravenously, by slow infusion (10 to 50 ml).

Doses and duration of treatment depend on the nature and severity of the disease, as well as the age of the patient. Single doses of up to 50 ml may be prescribed, but a course of treatment is preferable. The recommended optimal course of treatment is daily injections for 10-20 days.

Acute conditions (ischemic stroke, traumatic brain injury, complications after neurosurgical operations) – from 10 to 50 ml.

Residual period of cerebral stroke and traumatic brain and spinal cord injury – from 5 to 50 ml.

Psychoorganic syndrome and depression – 5 to 30 ml.

Alzheimer’s disease, dementia of vascular and combined Alzheimer’s-vascular genesis – 5 to 30 ml.

In neuropediatric practice, 0.1-0.2 ml/kg.

To increase the effectiveness of treatment, repeated courses may be given as long as there is improvement of the patient’s condition due to treatment. After the first course, the frequency of dosing may be reduced to 2 or 3 times per week.

Doses of 10 to 50 ml are recommended to be administered only by slow intravenous nfusions after dilution with the suggested standard solutions for infusion. The duration of infusions is 15 to 60 minutes.

Interaction

Taking into account the pharmacological profile of Cerebrolysin, special attention should be paid to possible additive effects when coadministered with antidepressants, including MAO inhibitors. In these cases, it is recommended to reduce the dose of the antidepressant.

Cerebrolysin and balanced amino acid solutions should not be mixed in the same infusion solution.

Cerebrolysin is not compatible with solutions that contain lipids and with pH-altering solutions (5-8).

Special Instructions

The drug’s compatibility has been tested and confirmed (for 24 hours at room temperature and lighting) with the following standard solutions for infusion:

• 0.9% sodium chloride solution (9 mg NaCl/ml);
• Ringer’s solution (Na⁺ – 153.98 mmol/L; Ca²⁺ – 2.74 mmol/L; K⁺ – 4.02 mmol/L; Cl^– – 163.48 mmol/L).
• 5% glucose solution.

Cerebrolysin may be given simultaneously with vitamins and drugs that improve cardiac circulation, but these drugs should not be mixed in one syringe with Cerebrolysin. Only the clear solution should be used and only once.

The effect on the ability to drive and operate machinery. Clinical trials have shown that Cerebrolysin has no effect on the ability to drive vehicles and operate machinery.

Contraindications

• individual intolerance to the drug
• acute renal failure
• Epileptic status.

.

Side effects

Reaction to administration: if administered too quickly, rarely a fever, sweating, dizziness; in single cases, palpitations or arrhythmias may occur. Therefore, the drug should be administered slowly.

Gastrointestinal disorders: rare – loss of appetite, dyspepsia, diarrhea, constipation, nausea and vomiting.

CNS and peripheral nervous system disorders: in rare cases, the presumed effect of activation was accompanied by agitation (manifested by aggressive behavior, confusion, insomnia). There have been reports of the occurrence in single cases (

On the immune system: extremely rare – hypersensitivity reactions or allergic reactions manifested by headache, pain in the neck, extremities, lower back, shortness of breath, chills and collaptoid condition.

Local reactions: rarely – redness of the skin, itching and burning at the injection site.

Others: extremely rare – cases of hyperventilation, arterial hypertension, arterial hypotension, fatigue, tremor, depression, apathy, dizziness and flu-like symptoms (cough, runny nose, respiratory infections) have been reported in studies.

Please note that some adverse effects (agitation, hypertension, hypotension, lethargy, tremor, depression, apathy, dizziness, headache, dyspnea, diarrhea, nausea) have been reported in clinical trials and occurred equally in patients receiving Cerebrolysin as in patients in the placebo group.

Pregnancy use

The drug is administered with caution in the first trimester of pregnancy and during lactation.

Cerebrolysin should only be used during pregnancy and lactation after careful consideration of the benefit-risk ratio of the treatment.

The results of experimental studies do not suggest that Cerebrolysin has teratogenic action or toxic effect on the fetus.

There have been no similar clinical studies, however.